The Effects of Preoperative Clinical and Radiological Results on the Prognosis in Patients Diagnosed with Oligodendroglioma

Öz

Oligodendroglial tumors are the third most common primary glial originated intracranial tumors. According to the World Health Organization central nervous system histopathological classification, Oligodendrogliomas are classified as Grade II (classic) or Grade III (anaplastic). The aim of this study is to retrospectively analyze the risk factors of recurrence during the follow- up period of the patients who were diagnosed with Oligodendroglioma Grade II or Grade III in our clinic. This study includes 18 patients who have been operated in Dokuz Eylül University Medical Faculty Department of Neurosurgery between 2008 and 2013 with pathology results compatible with Grade II or Grade III Oligodendroglioma. The study consisted of 12 males (66.7%) and 6 females (33.3%). The average age of the patients was 45.22±11.41 (Age range: 26-65). 6 patients (33.3%) were diagnosed with Oligodendroglioma (WHO Grade II), 12 (66.7%) with Anaplastic Oligodendroglioma (WHO Grade III). When the subgroups, which were divided into WHO Grade 2 and 3 by histopathological results, were compared according to the radiological results, a significant statistical difference has not been determined between calcification (p=0.596), midline shift (p=0,393), tumor location (p=0.193), and death rate (0.193).  In the future bioindicators and molecular studies will be used in the diagnosis and follow up of tumors and the risk factors that cause recurrence will be defined in more details.

Anahtar Kelimeler

• Anaplastic,Grade 2,Grade 3,Oligodendroglioma,Recurrence

Oligodendrogliom Tanısı Alan Hastaların Preoperatif Klinik ve Radyolojik Sonuçlarının Prognoza Etkisi

Öz

Oligodendroglial tümörler en sık görülen üçüncü intrakranyal glial hücre kökenli  primer beyin tümörleridir. Oligodendrogliomlar Dünya Sağlık Örgütü (DSÖ) santral sinir sistemi tümörlerinin histolojik sınıflandırmasına göre Derece 2 (klasik) veya Derece 3 (anaplastik) olarak sınıflandırılmaktadır. Bu çalışmanın amacı kliniğimizde oligodendrogliom tanısı alan hastaların takiplerinde rekürrense sebep olan risk faktörlerinin retrospektif analizini yapmaktır. Bu çalışma 2008-2013 yılları arasında Dokuz Eylül Üniversitesi Tıp Fakültesi Beyin ve Sinir Cerrahisi Kliniğinde ameliyat edilen ve patoloji sonucu Derece 2 ve 3 oligodendrogliom ile uyumlu olan 18 hastayı kapsamaktadır. Çalışmamızdaki hastaların 12’si (% 66.7) erkek ve 6’sı (% 33.3) kadın idi. Hastaların başvuru yaş ortalaması 45.22±11.41 (aralık 26-65) idi. Hastaların 6’sı  (% 33.3) oligodendrogliom (DSÖ derece II),  12’si (%66.7) anaplastik oligodendrogliom (DSÖ derece III) olarak değerlendirildi. Patoloji sonuçlarına göre DSÖ derece 2 ve derece 3 olarak ikiye ayrılan gruplar radyolojik görüntüler eşliğinde karşılaştırıldığında; kalsifikasyon (p=0.600), orta hat şifti (p= 0.316), tümör lokasyonu (p= 0.114) ve ölüm oranı (p= 0.114) arasında istatistiksel olarak fark saptanmadı. Gelecekte biyobelirteçler ve moleküler çalışmalar tümör tanı ve takibinde kullanılacak, rekürrense sebep olan risk faktörleri daha ayrıntılı tanımlanacaktır.

Anahtar Kelimeler

• Anaplastik,Derece 2,Derece 3,Oligodendrogliom,Rekürrens

Kaynakça

1. 1. Ostrom QT, Gittleman H, Liao P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014;16(Suppl 4):1–63.
2. 2. Aldape K, Nejad R, Louis DN, Zadeh G.Integrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community. Neuro Oncol. 2017;19(3):336-344.
3. 3. Louis DN, Perry A, Reifenberger G et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803-20.
4. 4. Wesseling P, van den Bent M, Perry A. Oligodendroglioma: pathology, molecular mechanisms and markers.. Acta Neuropathol. 2015;129(6):809-27.
5. 5. Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001;7: 839–45.
6. 6. Olson JD, Riedel E, DeAngelis LM. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology. 2000;54(7):1442–8.
7. 7. Lebrun C, Fontaine D, Ramaioli A et al. Long-term outcome of oligodendrogliomas. Neurology. 2004;62(10), 1783–7.
8. 8. Smits M. Imaging of oligodendroglioma. Br J Radiol. 2016;89(1060):20150857.

9. 9. Wessels PH, Weber WE, Raven G, et al. Supratentorial grade II astrocytoma: biological features and clinical course. Lancet Neurol 2003;2(7):395–403.
10. 10. Van Den Bent MJ, Bromberg JE, Buckner J. Low-grade and anaplastic oligodendroglioma.. Handb Clin Neurol. 2016;134:361-80.
11. 11. Oktar N, Biray C. Moleküler Tedavide Hedefteki İlk Tümör: Oligodendrogliomlar Türk Nöroşirürji Dergisi. 2005;15(2):130-5. 12. Olson JD, Riedel E, DeAngelis LM. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology. 2000;54(7):1442–8.
12. 13. Koeller KK, Rushing EJ. From the archives of the AFIP: oligodendroglioma and its variants: radiologic-pathologic correlation. Radiographics. 2005;25:1669–88.
13. 14. Chaichana KL, McGirt MJ, Niranjan A, Olivi A, Burger PC, Quinones-Hinojosa A. Prognostic significance of contrastenhancing low-grade gliomas in adults and a review of the literature. Neurol Res. 2009;31(9):931-9.
14. 15. Scott JN, Brasher PM, Sevick RJ, Rewcastle NB, Forsyth PA. How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology. 2002;59:947–9.
15. 16. White ML, Zhang Y, Kirby P, Ryken TC. Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas? AJNR Am J Neuroradiol. 2005;26:784–90.
16. 17. Hlaihel C, Guilloton L, Guyotat J, Streichenberger N, Honnorat J, Cotton F. Predictive value of multimodality MRI using conventional, perfusion, and spectroscopy MR in anaplastic transformation of low-grade oligodendrogliomas. J Neurooncol. 2010;97(1):73-80.
17. 18. Lebrun C, Fontaine D, Ramaioli A et al. Nice Brain Tumor Study Group. Long-term outcome of oligodendrogliomas. Neurology. 2004; 62(10):1783-7.
18. 19. Park CK, Kim JH, Moon MJ et al. Investigation of molecular factors associated with malignant transformation of oligodendroglioma by proteomic study of a single case of rapid tumor progression. J Cancer Res Clin Oncol. 2008;134(2):255-6.
19. 20. Fellah S, Caudal D, De Paula AM et al. Multimodal MR imaging (diffusion, perfusion, and spectroscopy): is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis? AJNR Am J Neuroradiol. 2013; 34: 1326–33.